Home Finance Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations – Yahoo Finance

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations – Yahoo Finance

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations – Yahoo Finance

NJ’s well established Biopharma infrastructure and highly skilled workforce will facilitate Tevogen’s growth
The dynamic medical innovation ecosystem of NJ offers significant opportunities to collaborate
Proximity to world-class global transportation hub and Tevogen’s R&D facilities will add further operational efficiency
METUCHEN, N.J., February 07, 2022–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in developing cell and gene therapies in oncology and viral infections, today announces opening of its new corporate office at 15 Independence Boulevard, Warren, New Jersey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220207005866/en/
Tevogen Bio new corporate hub, Warren NJ (Photo: Business Wire)
The facility, located in New Jersey’s biotech corridor, will serve as the company’s central location for corporate operations and was selected after thorough countrywide market research. Proximity to biopharma service providers in the area, mature medical innovation ecosystem and access to the specialized talent pool within commutable distance from this location will support the company’s expected rapid expansion in cell and gene therapy business.
Tevogen CEO Ryan Saadi, M.D., M.P.H., said, "Our corporate hub represents an important operational next step to best strategically support the diversification and expansion of our portfolio of T cell immunotherapies." Within 18 months of inception, the company has invented and secured several US patents, moved its lead product from discovery to clinical trial, and achieved manufacturing readiness. "This rapid progress directly contributed to cost efficiency and is a testament to the business prudence of our leadership. We believe this agile, cost-efficient and population centric business model along with disruptive science are critical to succeed in the post pandemic world," Saadi added.
About Tevogen’s T cell Technology, Investigational COVID-19 Therapy and Pipeline Targets
Tevogen’s off-the-shelf allogeneic T cell technology overcomes the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing. Tevogen’s current intellectual property portfolio includes several disruptive cell and gene therapy platforms which are internally invented and solely owned by the company. These breakthrough innovations open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.
The company’s lead product, TVGN-489 is currently in clinical trials for high-risk patients at Jefferson University Hospitals in Philadelphia. Tevogen recently announced it has completed dosing of the second cohort of patients in the proof-of- concept clinical trial of TVGN-489, marking the midway point of the trial’s planned four dosing levels. Trial details and recruitment information are available at Clinical Trials – Tevogen.
TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, which is designed to detect targets spread across the entire viral genome. These targeted CTLs are designed to recognize and kill off virally infected cells, hopefully allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.
The company also recently announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes.
About Tevogen Bio
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
Forward Looking Statements
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the "Company") development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220207005866/en/
Katelyn Joyce
Corporate Communications Lead
Biotech stocks are going through a historic drawdown at the moment. Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. Many of these beaten-down biotech stocks will ultimately rebound.
Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company to use
Medicare is designed to help with healthcare expenses for people aged 65 and older, certain younger people with disabilities and people with end-stage renal disease. The Medicare Extra Help program offers additional assistance with paying for prescription drugs for people … Continue reading → The post Medicare Extra Help Basics appeared first on SmartAsset Blog.
Rinvoq was recently authorized in the U.S. as a treatment for patients with moderate-to-severe eczema.
CBS News Bay Area anchor Allen Martin asks Dr. Anne Liu from Stanford Health Care about the Novavax COVID-19 vaccine and what makes it different from the current vaccines, and about concerns about dropping current restrictions at schools as some local doctors have recently pushed for
Rita Ora shows off toned abs in a black string bikini in a new Instagram photo selfie from Australia. The singer loves doing HIIT and circuits to stay fit.
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
Many Asian countries are facing a spike in COVID-19 infections after the widely-celebrated Lunar New Year holidays, as health officials grapple with the highly-transmissible omicron variant and expectations that numbers will continue to rise in coming weeks. The Lunar New Year, which is China’s biggest holiday, was celebrated across Asia on Feb. 1 even as pandemic restrictions in many countries kept crowds and family outings to a minimum. Hong Kong’s authorities are confronting record cases that are straining its so-called “zero-COVID” policy.
The CDC has shortened the amount of time people who are moderately or severely immunocompromised need to wait before getting a fourth COVID vaccine booster dose.
We can move on from COVID if we can convince everyone to get the vaccine. It's the only way forward. It’s a matter of life or death, not freedom.
Photo Illustration by Kristen Hazzard/The Daily Beast/GettyIn May 2020, I injured my ankle so badly I couldn’t move a toe. The slightest twitch sent a paralyzing bolt through my leg—like head-splitting microphone feedback that makes you recoil and cover your ears. That’s what back labor felt like—but in my spine.My baby was “sunny side up”—a vaguely appetizing term that meant his head was pushing against my spine. Every time I had a contraction, it felt like my back was breaking. The pain felt u
Untreated disease, violence, exposure, overdoses and car strikes are all added hazards of living on the streets Tents lined up on San Pedro on skid row, in downtown Los Angeles. Photograph: Robert Gauthier/Los Angeles Times/Getty Images The number of Americans dying while homeless has surged dramatically in the past five years, an exclusive analysis by the Guardian in conjunction with an academic expert at the University of Washington has shown. An examination of 20 US urban areas found the numb
The eyes are often called "the windows to the soul," but more often they can be a window to your health. Experts say that in particular, there's one subtle change that can tip you off to a problem involving your heart. They warn that if you notice this symptom in your eyes, it could signal high cholesterol—and the younger you are, the more likely it is to be the culprit. Read on to find out which ocular symptom could spell trouble for your heart health, and when you shouldn't worry.RELATED: Eati
The fact-checking podcast Science Vs interviewed scientists doing research that Malone cited in the interview. “Cherry Picking Data”: How Joe Rogan’s Infamous Interview with Robert Malone Spread Misinformation Wren Graves
Beatrice StouvenelFor years now, researchers from the Swiss Federal Institute of Technology (EPFL) in Lausanne have been working on a groundbreaking approach to reverse paralysis in people with spinal cord injuries, by reactivating dormant neurons with electrical stimulation.The treatment has now taken a massive leap forward, thanks to new findings published in Nature Medicine in which vertebrae implants restored the ability to walk and move around in three paralyzed patients—all in just a matte
"Any mask is better than no mask," the CDC says, urging Americans to wear N95 masks for the best protection against COVID-19.
Heart disease is the number one killer in the country, according to the Centers for Disease Control and Prevention, and "'heart disease' refers to several types of heart conditions. In the United States, the most common type of heart disease is coronary artery disease (CAD), which can lead to heart attack." Over 16 million Americans have cardiovascular disease (CVD), which includes heart disease, stroke, hypertension and heart failure, the National Center for Biotechnology Information, U.S. Nati
Andrew Markert respects the coronavirus. It has messed with his livelihood, a D.C. pub called Beuchert's Saloon, forcing him to close, move outdoors and adjust in countless other ways. But the time has arrived for him to move forward and stick to his plans, come what may in the next round of the pandemic. And he's betting there are a lot of people like him.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. So Markert plans to open not o
The older you get, the more slowly you heal, and there are a number of reasons why. Westend61 via Getty ImagesI recently visited an 83-year-old patient in the hospital after EMTs rushed her to the ER with an infected leg wound. Her ordeal started inconspicuously when she bumped into the sharp edge of a table and developed a small cut. The patient’s wound didn’t close, but she ignored it until she woke up in pain one morning two weeks after first injuring her leg. Her daughter called 911 after no
Novavax in July 2020 had received $1.6 billion in funding to develop its protein-based vaccine under a government program aimed at accelerating access to coronavirus vaccines and treatments, formerly called Operation Warp Speed. Novavax's two-dose shot has received authorizations from the European Union and the World Health Organization and was recently cleared for use in adults in Britain and New Zealand. Novavax last year started testing its vaccine in adolescents aged 12 to 17.



Please enter your comment!
Please enter your name here